SYK Pathway
Cross-source consensus on SYK Pathway from 1 sources and 3 claims.
1 sources · 3 claims
How it works
Comparisons
Highlighted claims
- The SYK pathway was identified as a candidate therapeutic target in COVID-19, being activated by C-type lectin receptors, C-type lectin-like receptors, and Fc receptors. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- SYK inhibition had been shown to inhibit platelet aggregation in heparin-induced thrombocytopenia models, a disease sharing mechanistic features with COVID-19. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- SYK inhibition suppresses platelet activation and cytokine release, both of which are critical events in COVID-19 pathogenesis. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic